CRNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Crinetics Pharmaceuticals (CRNX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, positive revenue growth from its first commercial product (PALSONIFY), significant hedge fund buying, and robust cash reserves make it a compelling opportunity despite near-term technical neutrality.
The stock's MACD is slightly negative and contracting, RSI is neutral at 41.005, and moving averages are converging, indicating no clear short-term trend. The stock is trading near its pivot point (44.686), with key support at 42.226 and resistance at 47.146. Overall, the technical indicators suggest a neutral trend in the short term.
Successful launch of PALSONIFY with strong early adoption and revenue generation.
Analysts have raised price targets significantly, with targets ranging from $84 to $105, citing strong product performance and pipeline execution.
Hedge funds have increased their buying activity by 448.61% over the last quarter.
The company has over $1 billion in cash reserves, with an expected increase to $1.4 billion, ensuring financial stability for future growth.
Increased operating expenses planned for 2026, which could weigh on profitability in the near term.
Technical indicators show no clear bullish momentum, and short-term stock trend analysis suggests potential minor declines in the next week and month.
No recent congress trading data or AI trading signals to support immediate buying action.
In Q4 2025, Crinetics reported $6.2 million in revenue, with $5.4 million from PALSONIFY's U.S. sales. The company has shown improvement in net income (-130.09M, up 69.33% YoY) and EPS (-1.38, up 43.75% YoY). Gross margin remains at 100%. The company is financially stable with over $1 billion in cash reserves and plans to reach $1.4 billion after a public offering.
Analysts are overwhelmingly positive on CRNX, with multiple firms raising price targets significantly (e.g., Stifel to $84, Morgan Stanley to $87, Evercore ISI to $90, and JonesResearch to $97). Analysts highlight strong early performance of PALSONIFY, a promising pipeline, and potential blockbuster drugs in development as key drivers for growth.
